Poxel Provides 1Q16 Cash Figures
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of novel products to treat type 2 diabetes, today announced its cash position for the first quarter 2016.
As of March 31, 2016, unaudited cash and cash equivalents were €37.3 million, as compared to €32.8 million as of March 31, 2015.
As expected, Poxel did not generate significant revenues in either the first quarter of 2016 or 2015.
These figures are consistent with the Company’s expectations and its growth strategy, which remains focused on the clinical development of its diabetes drug candidates Imeglimin and PXL770.
Next financial press release: first half 2016 cash position expected on July 15, 2016
About Poxel
Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have entered Phase 2b clinical development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160504006346/en/
Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior
Vice President, Investor Relations and Public Relations
[email protected]
or
Investor
relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen
Schweitzer, + 49 89 2424 3494
or
Stephanie May, + 49 175 571
1562
[email protected]
or
Investor
relations / Media - France
NewCap
Florent Alba/Nicolas
Mérigeau, + 33 1 44 71 98 55
[email protected]
Source: Poxel SA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LaPhair Capital Partners Acquires Kinexx Modular Construction to Accelerate Homeownership in Urban Communities
- Zealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide Medicines
- Veritonic Doubles Down on Mobile Audio Attribution by Integrating with AppsFlyer
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!